Skip to main content

Table 3 Embolic events

From: Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity

A

CMET+

CMET–

p†

Overall

   

 All embolic events

21% (24)

8% (9)

0.006

 Pulmonary embolism*

13% (14)

5% (6)

0.08

 CVA†

8% (9)

4% (4)

0.23

 Peripheral embolism

5% (5)

0% (–)

–

Right-sided involvement (n = 65)

   

 All embolic events

31% (20)

8% (5)

0.001

Pulmonary embolism

20% (13)

6% (4)

0.02

 CVA

9% (6)

3% (2)

0.22

 Peripheral embolism

8% (5)

0% (–)

–

Left-sided involvement (n = 56)

   

 All embolism

13% (7)

7% (4)

0.55

 Pulmonary embolism

4% (2)

5% (3)

1.00

 CVA

7% (4)

2% (1)

0.38

 Peripheral embolism

2% (1)

0% (–)

–

Intra-cavitary metastasis

   

 Right-sided Involvement (n = 45)

   

  All embolic events

36% (16)

9% (4)

0.002

  Pulmonary embolism

27% (12)

7% (3)

0.01

  CVA

11% (5)

4% (2)

0.38

  Peripheral embolism

7% (3)

0% (-)

-

 Left-sided Involvement (n = 31)

   

  All embolic events

29% (9)

10% (3)

0.15

  Pulmonary embolism

16% (5)

7% (2)

0.45

  CVA

13% (4)

3% (1)

0.38

  Peripheral embolism

3% (1)

0% (-)

-

B

Heterogeneous enhancement CMET+

(n = 59)

Diffuse enhancement CMET+

(n = 53)

P

All embolic events

24% (14)

19% (10)

0.53

Pulmonary embolism

15% (9)

9% (5)

0.35

CVA

10% (6)

6% (3)

0.50

Peripheral embolism

2% (1)

8% (4)

0.19

  1. *Pulmonary embolism
  2. †Cerebrovascular events